Board of Directors
Bradley E. Patt, PhD (Chairman and Chielf Executive Officer)
Dr. Patt is cofounder chairman and CEO of Tetrous.
Brad has over 30 years experience as an entrepreneur and executive manager. He has led several enterprises from start-up phase through rapid growth and merger and acquisitions.
Brad founded several high tech ventures since 1997. He is currently co-founder chairman and CEO of TheraCell and DermOQ. Previously he was co-founder, CEO and Chairman of Gamma Medica, Inc. Brad built Gamma to market leadership position in preclinical CT, PET, SPECT imaging and is inventor and developer of Molecular Breast Imaging for detecting otherwise occult breast cancer in densebreasted women.
Brad is also cofounder and Director of EVO Worldwide, Inc. and spin off Smart Breast Corp., medical diagnostic imaging systems companies; DxRay, Inc. an advanced digital xray detection company; sold to Rapiscan (OSI Systems in 2017); Photon Imaging, Inc. a technology incubator; and Radiant Detector Technologies, Inc., sold to Seiko of Japan in 2005 now operating as Hitachi High Technology, USA, Inc. Brad is co-founder and chairman of Hyvida Brands, a functional beverage startup; and is a director of High Beauty a cannabis cosmetic company. Brad also founded and is a Director of Thrive Outside the Box, a nonprofit organization that identifies and develops areas of talent in individuals on the autistic spectrum.
Brad is an internationally recognized authority in the field of medical imaging with over one hundred scientific papers and presentations, several book chapters, and over 20 patents. He has been an invited speaker at several international conferences. He has held elected positions on the IEEE Nuclear Medicine Instrumentation Steering Committee (NMISC) and the IEEE Radiation Instrumentation Steering Committee (RISC), and was appointed to the Program Committee of the SPIE Medical applications of Penetrating Radiation, acting as Chairman of the Penetrating Radiation Work Group for 2003 and 2004. Dr. Patt is a consultant to the National Institutes of Health and the recipient of over $15 million dollars of grant awards as Principal Investigator from the National Institutes of Health, The United States Department of Energy and NASA.
Andrew J. Carter, PhD ‐ Director and Chief Technology Officer
Andy is cofounder, Director and Chief Technology Officer of Tetrous. He has worked with TheraCell as Chief Technology Officer since March 2011 and has more than 30 years leadership experience in the medical device industry and is an expert in orthobiologics, orthopaedics, and biomaterials with more than 30 US patents and patent applications. He is a cofounder and Chief technology Officer of DermOQ, a TheraCell spinoff company.
Andy is also Adjunct Associate Professor at the Prince of Wales Clinical School, UNSW, Sydney, Australia. Previous experience includes being the founder and President of Accent Biomedical, a provider of innovation services, and Chief Technology Officer at Anika Therapeutics, NASDAQ listed developer of hyaluronic acid based products for orthopedics, ophthalmics and aesthetic dermatology. Prior to this he was Vice President R&D and General Manager at Spine Wave Inc. a Connecticut based start up spine company. There he was responsible for development of injectable nucleus replacement and other motion preserving technologies. Andy spent over twenty years at Smith & Nephew, both in the US and UK. As Group Director of R&D at Smith & Nephew Endoscopy in Boston, USA he led 80+ engineers developing implants, RF and mechanical resection systems, fluid management systems for arthroscopy and endoscopy applications. He also led the company’s successful efforts to improve the effectiveness of the product development process. As Program Manager for Orthopedics and Endoscopy and Head of Materials Research at Smith & Nephew’s Group Research Center in York, UK he formulated and led long term research programs in orthopedics, spine and endoscopy, setting up joint ventures in tissue engineering and collaborative research programs with numerous universities.
Nikhil N. Verma, MD
Nikhil N. Verma MD serves patients as a shoulder, elbow and knee orthopaedic surgeon at Midwest Orthopedics at Rush, one of the top academic private practices in the nation. As a physician-leader with many interests, Dr. Verma also serves as the Head Team Physician for the Chicago White Sox, a Team Physician for the Chicago Bulls and Fellowship Director and Chief of the Sports Medicine Division of Orthopaedic Surgery at Rush University Medical Center. Dr. Verma balances his clinical and research efforts, leading various clinical trials evaluating autologous stem cell therapies for various orthopedic ailments including rotator cuff tears, ACL reconstruction, meniscectomy and knee osteoarthritis.
A graduate of University of Pennsylvania’s School of Medicine, Dr. Verma completed his orthopaedic residency at Rush-Presbyterian-St. Luke’s Medical Center. His training culminated in a sports medicine and shoulder surgery fellowship at the Hospital for Special Surgery, where he received world-class training on the treatment of shoulder and elbow disorders in overhead throwing athletes. He is particular active in orthopaedic research with interests in basic science, biomechanics and clinical outcomes, and has recently received funding for his research from Major League Baseball.
As an innovator, Dr. Verma has worked to develop and license various sports medicine implants and instruments used by orthopaedic surgeons across the United States. He is an active consultant for a host of medical device companies and sits on committees for various publication journals, including the American Orthopaedic Society for Sports Medicine (AOSSM), American Shoulder and Elbow Surgeons (ASES) and the Arthroscopy Association of North America (AANA).
Frank Philips, MD
Dr. Frank Phillips is a partner at Midwest Orthopaedics and is Professor of Orthopaedic Surgery, Spine Fellowship Co-Director and Head, Section of Minimally Invasive Spine Surgery at Rush University Medical Center. Dr. Phillips has pioneered numerous minimally invasive spine procedures and techniques that are now widely used and has published extensively in this field. He has over 15 patents in this space and has authored more than 150 peer reviewed publications and book chapters. He has participated as principal investigator in cervical disc replacement FDA trials. Dr. Phillips has held numerous leadership positions and is currently a Board Member and North American President of the Society for Minimally Invasive Spine Surgery (SMISS) and is also Program Chair for the SASS Annual Meeting. He regularly teaches and lectures to spine surgeons nationally and internationally on spinal surgery.
Dr. Phillips served on BODs of Kyphon (acquired by Medtronic in 2007 for $4 billion) and on the Boards of other privately and publicly held spinal companies. He has also participated as a founder in a number of successful spine start-ups.
Gunnar Andersson, MD, PhD
Dr. Gunnar Andersson is The Ronald L. DeWald, M.D. Professor and Chairman Emeritus of the Department of Orthopedic Surgery at Rush University Medical Center and a Spine, Back & Neck Surgeon at Midwest Orthopedics at Rush in Chicago, IL. He was chairman of the Department of Orthopedic Surgery from 1994 to 2008.
Dr. Andersson has been at the forefront of spine surgery research and education for more than 30 years. He is a member of 17 editorial boards, editor-in-chief of Spinal News International, a deputy editor for Spine, founding editor of Contemporary Spine Surgery and an associate editor of Clinical Biomechanics. He is the author of over 330 original publications, over 160 books and book chapters and over 530 abstracts.
Dr. Andersson is a past president of the Orthopaedic Research Society, the International Society for the Study of the Lumbar Spine and the American Academy of Disability Evaluating Physicians and is currently President of the International Society for the Advancement of Spine Surgery.
Dr. Andersson’s activities in connection with commercial companies includes previously being a member of scientific advisory boards at Zimmer, Smith and Nephew, Oratec, Pioneer, Angstrom, St Francis, and Bioset. He is currently on the scientific advisory boards at Allosource, Ouroboros, and Spinal Kinetics, and is a member of the safety monitoring boards at Spinal Kinetics and ISTO. Dr. Andersson is also on the Spine Advisory board to United Healthcare.
Jan S Iwanczyk, PhD
Jan Iwanczyk is a board member and a co-founder of Theracell, Inc. He is also a co-founder and CEO of DxRay Inc., Chairman & President of Photon Imaging, Inc., co-founder of Radiant Detector Technologies, Gamma Medica, Inc. and EVO Worldwide, Inc. Dr. Iwanczyk was awarded the 2002 Merit Award from the IEEE Nuclear and Plasma Sciences Society and has published over 150 scientific papers.
Dr. Iwanczyk received his Doctorate in Physics from the Electronics Institute of Nuclear Research in Swierk, Poland and his B.S. and M.S. in Electronics from Warsaw Technical University in Warsaw, Poland.
Simon Berry has 25 years of management and business development experience in the healthcare and medical manufacturing market. This included a national role for Smith & Nephew Richards specialising in joint replacement implants, biologics and trauma based products for Orthopaedic surgery. Simon was appointed to introduce endoscopic camera technology for the commencement of laparoscopic surgery in Australia. Simon was the also a designer and manufacturer of several laparoscopic instruments which have since been sold to major device organisations. In 1997, Mr. Berry was offered a long term contract with Wright Medical Technology to distribute orthopaedic technologies with a key focus on the introduction of the first types of Biologics for bone grafting which led to an interest in Allograft surgery. Mr. Berry is a founding member, CEO and Company Director of Australian Biotechnologies In 2002 Mr. Berry founded Australian Biotechnologies with several orthopaedic surgeons with a vision to provide allografts and new tissue technologies to Australia. Under his direction the company has grown to be the largest manufacturer of allografts in Australia and has partnerships with most Australian Health Departments to process donated tissue. In 2017 he expanded the Australian Biotechnologies operations to the USA in partnership with the Nevada Donor Network to form Origin Biologics which now has an FDA approved manufacturing facility in Las Vegas.